All enrolled people who been given at the least just one dose of zosuquidar or placebo throughout induction were monitored to the occurrence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse functions ended up connected with the period of extended and sizeable myelosuppression https://michaelw009grb1.wssblogs.com/profile